Finally, Table 15, which is a reprint of Table 11 from the CY 2026 OPPS/ASC proposed rule (90 FR 33535), shows the comment timeframe for new and revised HCPCS codes
In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
The typical formulation contains semaglutide at 5 mg/mL, glycine at 5 mg/mL, and cyanocobalamin (vitamin B12) at 1 mg/mL
NHSE&I Procurement of Digital Weight Management BDA response
This wide array of potential applications makes it a compelling subject for continued scientific inquiry
Molnr M, St T, Tth T, Hertelendy F